RXRX vs AGIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RXRX · Recursion Pharmaceuticals$2.45 ▼ 9.93%
AGIO · Agios Pharmaceuticals$27.60 ▼ 4.03%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RXRX -43.4%
- AGIO +4.2%
Head to head
| Metric | RXRX | AGIO |
|---|---|---|
| Price | $2.45 | $27.60 |
| Change today | ▼ 9.93% | ▼ 4.03% |
| Market cap | $1.53B | $1.65B |
| Return, 3 months | -24.6% | -15.4% |
| Return, year to date | -40.1% | +1.4% |
| Return, 1 year | -41.2% | +9.4% |
| P/E (TTM) | – | – |
| P/B | 1.7 | 1.7 |
| P/E percentile vs own 5y | 67th | 48th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +262.3% | +330.0% |
| Net profit growth (YoY) | +26.6% | +37.1% |
| Gross margin | 27.9% | 93.8% |
| Operating margin | -738.7% | -297.7% |
| Net margin | -709.8% | -264.8% |
| Return on equity | -48.7% | -32.9% |
| Analyst target vs. price | +170.6% | +65.9% |
| Analyst buy share | 50% | 67% |
| RSI (14) | 31 | 35 |
| 30-day volatility | 103.2% | 86.1% |
| Max drawdown, 1 year | -50.6% | -50.9% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AGIO is the largest of the group by market value.
- AGIO has returned the most over the past year.
- AGIO is growing revenue fastest.
- AGIO keeps the most profit per dollar of sales.
- AGIO has been the calmest stock over the last 30 days.